OPHIDION, INC is developing a new class of safe and effective drugs targeting some of the most important receptors in the central nervous system. They are targeting relief of the symptoms of schizophrenia, ADHD, Parkinson’s disease, and Alzheimer’s disease, as well as addiction and anxiety. The founder launched the company in the Pasadena Bioscience Collaborative and located at TechVentures when she joined the Lehigh University faculty.


Industry Biomedical
Focus Areas
Focus Areas - detailed Schizophrenia, ADHD, Parkinson’s, Alzheimer’s disease, addiction, anxiety, smoking cessation


University Lehigh, Rockefeller, Caltech
Principal Investigator Julie Miwa - Lehigh


Web http://nep.benfranklin.org/ophidion-inc-2/
Web http://pasadenabiosci.org/companies/ophidion/
Address Ben Franklin TechVentures, 116 Research Dr., Bethlehem PA 18015
Phone 610.758.3079 (Office at Lehigh University)
Email moc.oibnoidihpo|awim.eiluj#moc.oibnoidihpo|awim.eiluj


Smoking Cessation
Cholinergic Drugs

Key People


2009 - Founded

Intellectual Property

No files attached to this page.

Add a New Comment